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Abstract: Although pathological skin-picking has been documented in the medical literature 
since the 19th century, it has only recently been included as a distinct entity in psychiatric 
classification systems. In the Diagnostic and Statistical Manual of Mental Disorders, 5th Edi-
tion and the proposed International Classification of Diseases, Eleventh Revision, excoriation 
(skin-picking) disorder (ED), also known as neurotic excoriation, psychogenic excoriation, 
or dermatillomania), is described as recurrent picking of skin, leading to skin lesions and 
significant distress or functional impairment. ED is listed as one of the obsessive–compulsive 
and related disorders, given its overlap with conditions such as trichotillomania (hair-pulling 
disorder). Arguably, its inclusion and delineation in the diagnostic nomenclature will lead to 
increased awareness of the condition, more research, and ultimately in treatment advances. This 
systematic review aims to provide readers with an up-to-date view of current treatment options 
for ED. A MEDLINE search of the ED treatment literature was conducted to collate relevant 
articles published between 1996 and 2017. The findings indicate that a number of randomized 
controlled trails on ED have now been published, and that current management options include 
behavioral therapy (habit reversal or acceptance-enhanced behavior therapy), and medication 
(selective serotonin reuptake inhibitors or N-acetyl cysteine).
Keywords: excoriation, skin-picking, treatment, habit reversal therapy, behavioral therapy, 
pharmacotherapy, systematic review
Background
Excoriation (skin-picking) disorder (ED), also known as dermatillomania, psychogenic 
excoriation, or neurotic excoriation, is characterized by recurrent picking of skin, 
leading to skin lesions and significant distress or functional impairment.1 Although 
documented in the medical literature since the 19th century,2 ED has only recently 
been included as a distinct entity in mainstream psychiatric nosology. In the Diagnostic 
and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) and the proposed 
International Classification of Diseases, Eleventh Revision (ICD-11), ED is listed as 
one of the obsessive–compulsive and related disorders (OCRDs), given its overlap with 
conditions such as trichotillomania (TTM or hair-pulling disorder).
Arguably, the inclusion and delineation of ED in the updated diagnostic nomen-
clature will give impetus to increased recognition of this condition. Skin-picking is 
quite common, with prevalence estimates of ED ranging between 1.4% and 5.4%.3,4 
ED may occur at any age, but it generally has its onset in adolescence, typically coin-
ciding with the onset of puberty.5 The majority of individuals seeking treatment for 
ED are female.6 Dermatological conditions such as acne or eczema often trigger the 
onset of ED. Skin-picking triggers can be multiple, and may vary across individuals, 
but include emotions such as stress, anger, and anxiety, sedentary activities such as 
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watching television and reading, and boredom and feeling 
tired.7–9 Skin-picking may be from any area of the body, and 
usually occurs in multiple sites, most commonly in the face, 
followed by the hands, fingers, arms, and legs. Healthy skin 
and minor skin irregularities are also picked.
An inability to stop picking despite repeated efforts to do 
so is typical10 and may lead to shame, anxiety, and depres-
sion. Indeed, the clinical impact of the disorder should not be 
underestimated; individuals with ED often spend a significant 
amount of time on repetitive picking and/or camouflaging 
(adding up to several hours per day in severe cases), leading 
them to miss or be late for work, school, or social activities.11 
Different psychosocial sequelae, such as social embarrassment, 
avoidance of situations or activities where skin lesions can be 
detected, and loss of productivity in multiple settings, have also 
been reported.12 Possible medical sequelae include infections, 
lesions, scarring, and even serious physical disfigurement.13 ED 
is also associated with substantial comorbidity including other 
body-focused repetitive behavior disorders – with TTM being 
the most common. Obsessive–compulsive disorder (OCD) and 
body dysmorphic disorder (BDD) are more prevalent in individ-
uals with ED than in the general population. Mood and anxiety 
disorders are also common in ED. Cases have been documented 
where there was an increased risk of mortality.14,15
The severity of skin-picking ranges from mild to severe; 
in subclinical cases, intervention may not be needed, whereas 
when diagnostic criteria for ED are met, treatment is indi-
cated. However, individuals with ED may not commonly seek 
treatment for their condition.16 It has been suggested that less 
than a fifth of patients seek treatment for their skin-picking.11 
Reasons for not seeking help are, among others, social embar-
rassment, the belief that the condition is just a “bad habit”, 
or that it is untreatable.2 Those who do seek treatment often 
present to a general practitioner or to a dermatologist before 
consulting a psychiatrist or a psychologist.2
In terms of treatment, there is a paucity of data. Never-
theless, management currently relies on a comprehensive 
psychiatric examination, behavioral therapy, and medication. 
This systematic review aims to provide readers with an up-
to-date view of treatment options for ED.
Methods
A MEDLINE search via the PubMed interface of ED treat-
ment literature was conducted to collate relevant articles. Key 
search terms such as “excoriation disorder”, “skin-picking 
disorder”, “dermatillomania” and combinations thereof 
with “treatment”, “pharmacotherapy”, “medication”, and 
“psychotherapy”, with the use of the Boolean operators 
“and” or “or”, were used to identify relevant empirical 
studies and reports. In this review, we focused on randomized 
controlled studies, uncontrolled studies, meta-analyses, and 
systematic reviews published between 1996 and 2017. The 
search was limited to the literature in the English language. 
Publications on pathological skin-picking occurring in the 
context of another mental disorder (eg, BDD), substance use 
(eg, cocaine), or another medical condition (eg, scabies or 
Prader–Willi syndrome) were not included.
Results
Nonpharmacological treatment
A significant benefit for nonpharmacological treatments, 
such as cognitive-behavioral therapy (CBT) and habit rever-
sal therapy (HRT), in ED has been suggested.17,18
Cognitive-behavioral interventions
In the context of ED, CBT generally involves psychoedu-
cation, cognitive restructuring, and an emphasis on relapse 
prevention through enhancement of self-efficacy, as well as 
agreement on clearly defined measures to prevent or address 
relapse. It also includes behavioral interventions such as HRT 
which has previously been used to treat a variety of repetitive 
behavior problems such as cheek biting, oral-digital habits, 
and TTM19 and which entails awareness training and compet-
ing response training. Awareness training includes elements 
such as self-monitoring. In competing response training, 
the patient is taught how to substitute skin-picking with 
an incompatible action (eg, fist clenching). Including these 
these elements of HRT, a 4-week randomized controlled trial 
(RCT) for ED (n=34) demonstrated efficacy, with treatment 
effects maintained at 2-month follow-up.20 Another small 
controlled study suggested that patients with ED (n=19) 
treated with HRT over 3 sessions reported a greater decrease 
in skin-picking at post-treatment and follow-up compared to 
waiting list controls.21
Cognitive-behavioral interventions for ED may also be 
useful when presented in a self-help format that patients 
access themselves. Two studies to date have investigated 
the efficacy of such self-help interventions. The first, an 
uncontrolled study lasting ~3 months, investigated the effi-
cacy of an Internet-based self-help treatment derived from 
the evidence-based cognitive-behavioral model of ED, in 
151 patients.22 Results revealed significant reductions in 
symptom severity ratings from baseline to post-intervention, 
suggesting that this approach is worth further study and may 
provide an alternative or adjunctive treatment for ED. The 
second trial was a randomized controlled study that compared 
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HRT with decoupling (DC) – where the patient is taught 
how to “unlearn” picking (by replacing the skin-picking 
by a harmless behavior that mimics the central movements 
of the problematic behavior [eg, hand approaches the face 
where skin is picked]), but which then deviates to a differ-
ent location where picking does not occur (eg, the ear). This 
deviation constitutes the start of a new behavioral sequence 
that ends in a harmless action (decoupling). Here, both 
treatments were delivered using bibliotherapy over 4 weeks 
(also via the Internet). The results confirmed the efficacy of 
self-help HRT for ED but were less supportive for the use 
of DC in ED.23
Acceptance and Commitment Therapy (ACT), which 
entails acceptance and mindfulness strategies, as well 
as commitment and behavior change strategies, has also 
been investigated in ED. This type of CBT promotes the 
acceptance of negative thoughts and feelings as part of the 
human experience (“acceptance”) and encourages thinking 
of ways to respond to these negative thoughts and emo-
tions in a way that is congruent with personal values and 
goals (“commitment”) and not to engage in destructive 
behaviors such as skin-picking. In a preliminary study of 
five patients with ED, ACT led to a near complete cessation 
of skin-picking in four participants, but gains were not fully 
maintained in three of the four participants at follow-up.24 
In another small pilot study that examined the utility of a 
combination of ACT and HRT (also known as acceptance-
enhanced behavior therapy) for patients with TTM or ED, it 
was suggested that both these interventions greatly reduced 
pulling/picking for all participants (n=5) and that the order in 
which ACT and HRT were implemented made little or no dif-
ference in the short-term treatment outcome.25 Meta-analysis 
supports the benefits of these interventions in ED.18
Pharmacotherapy
In the last decade or two, the efficacy and tolerability of 
a number of pharmacological agents have been tested in 
ED, with studies including selective serotonin reuptake 
inhibitors (SSRIs), lamotrigine, glutamatergic agents such 
as N-acetyl cysteine (NAC) and riluzole, and opioid antago-
nists such as naltrexone. Augmentation strategies have also 
been investigated.
Selective serotonin reuptake inhibitors
A number of SSRIs have demonstrated improvement on 
measures of skin-picking behavior in ED.2 Nevertheless, 
study methods, including outcome measures, have varied. 
There have been two trials of fluoxetine (one an RCT and the 
other open-label), with both using a flexible dosing schedule 
up to either 80 mg/day over 10 weeks26 or 60 mg/day over 
6 weeks,27 respectively. The RCT suggested that fluoxetine 
improved symptoms significantly more than placebo, at a 
mean dosage of 55 mg/day; however, this improvement 
was supported by only one of the three outcome measures 
used.26 In the second fluoxetine study, 6 weeks of open-label 
fluoxetine was prescribed, followed by a 6-week double-blind 
discontinuation phase for responders. About half (53.3%) of 
the participants in the first open-label treatment phase were 
responders. Responders who were randomized to fluoxetine 
maintained their improvement during the double-blind dis-
continuation phase, whereas those on placebo returned to 
previous levels of picking severity.27 Some case reports also 
provide support for the use of fluoxetine in ED.28
One of the largest double-blind RCTs of an SSRI in ED to 
date (n=45) found some support for the efficacy of citalopram 
(20 mg/day, over 4 weeks).29 Here, the total score on the 
Yale-Brown Obsessive-Compulsive Scale decreased signifi-
cantly more with citalopram than with placebo. However, no 
significant differences were observed between the citalopram 
and placebo groups in terms of the primary outcome measure 
(a visual analogue scale).
An open-label trial of escitalopram, with a flexible dosing 
schedule of up to 30 mg/day over 18 weeks, suggested that 
this agent may also be efficacious in reducing pathological 
skin-picking.30 In this trial (n=29), almost half of the sample 
(44.8%) showed full remission of picking symptoms, with 
an additional 27.6% showing partial response. Significant 
main treatment effects were observed for all ED measures 
used. Another uncontrolled study using fluvoxamine, with a 
flexible dose range of 25–50 mg/day to a maximum total dose 
of 300 mg/day over a period of 12 weeks, reported that all 
participants (14/14) had a significant reduction in behaviors 
involving the skin (eg, scratching, picking, gouging, or 
squeezing), increased control over skin behavior, and a sig-
nificant improvement in the presence of skin sensations, skin 
appearance, and lesions.31 Sertraline, at flexible dose, using 
a flexible study timeline in another open-label trial, has also 
showed promise as an SSRI that can reduce skin-picking 
(68% response rate).32
Lamotrigine
Data on the efficacy of lamotrigine (an anti-epileptic agent) 
in ED are inconsistent. To date, there have been two trials of 
lamotrigine in ED, both following a flexible dosing schedule 
over 12 weeks.16,33 The first, an open-label trial (n=16),16 found 
a 67% response rate, suggesting some benefit for this agent in 
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
23
2.
12
5.
10
8 
on
 2
9-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1870
Lochner et al
ED. The second, a RCT (n=7),33 had a response rate of 43.8%, 
thus failing to demonstrate greater benefit than placebo.
Glutamatergic agents
There is growing interest in the use of glutamatergic agents in 
OCD, TTM, and other OCRDs.2,34,35 Glutamate is a key excit-
atory central nervous system (CNS) neurotransmitter, and the 
glutamatergic system has been targeted for pharmacologic 
manipulation in OCRDs. NAC, for example, is a nutraceuti-
cal agent that modulates the glutamatergic and neuroinflam-
matory systems. The potential benefit of NAC in ED has been 
suggested by case reports.36 In addition, a recent randomized, 
double-blind trial (dosing range 1,200–3,000 mg/d) over 
12 weeks found that NAC significantly reduced symptoms of 
ED.37 Almost half of the sample (15/32, 47%) receiving NAC 
were much or very much improved compared to 19% (4/21) 
of participants receiving placebo. There were, however, no 
significant differences in psychosocial functioning between 
the active and placebo trial arms. There also is anecdotal 
evidence for the efficacy of the glutamate-modulating agent 
riluzole in reducing skin-picking.38
Opioid antagonists
In acral lick dermatitis, a condition found in dogs and that 
constitutes a possible animal model of ED, a role for opioid 
antagonists such as naltrexone has been suggested.39,40 
In humans with ED, the efficacy of opioid antagonists is 
supported by case reports only.41
inositol
Inositol, an isomer of glucose that has traditionally been 
considered a B vitamin, is another neutraceutical interven-
tion that may be of use in ED; to date, there has been only 
one published uncontrolled study (n=3) that showed reduced 
picking at 16 weeks post follow-up.42 The mechanism by 
which this agent exerts its therapeutic effects remains to be 
elucidated, but it is possibly linked to a modulatory effect 
on 5-HT transporter activity.
Augmentation strategies
To our knowledge, there have been no RCTs to investigate 
the efficacy of augmentation strategies in ED. However, 
a number of case studies have provided support for augmenta-
tion with atypical and typical antipsychotic agents in reducing 
skin-picking. For example, addition of aripiprazole to the 
serotonin–norepinephrine reuptake inhibitor venlafaxine (the 
latter prescribed for anxiety and depression) ended picking in 
one case of treatment-resistant ED.43 In two other cases, flu-
oxetine was augmented with olanzapine44 or paliperidone,45 
resulting in reduced picking. Furthermore, case studies also 
support augmentation of SSRIs with typical antipsychotic 
agents such as haloperidol in ED.46
Alternative interventions
Alternative treatments, such as yoga, aerobic exercise, acu-
puncture, and hypnosis, either as monotherapy or as an adjunct 
to psychotherapy and/or pharmacotherapy, have been pro-
posed for the treatment of ED.47 However, no RCTs with 
these modalities have been undertaken.
Combined treatment
To our knowledge, there are no rigorous studies that have 
investigated the efficacy of combinations of psychotherapy 
and pharmacotherapy in ED yet.
Conclusion
ED is often a chronic disorder associated with substantial 
morbidity and comorbidity. Fortunately, a number of treat-
ment modalities are effective in reducing skin-picking 
behaviors. The literature systematically reviewed here, and 
previous meta-analyses, emphasize the relatively sparse 
evidence base, but also point to the benefit of behavioral 
treatments.17,18 SSRIs have been a mainstay of pharmacother-
apy, but there is now evidence from a RCT that NAC should 
also be considered as a potential intervention. There is a need 
for consensus on the optimal symptom severity measures, 
and for additional controlled trials, using both explanatory 
and pragmatic designs. In the interim, there is also a need to 
improve accessibility to efficacious treatments.
Acknowledgments
The authors are supported by the South African Medical 
Research Council.
Disclosure
Dr Stein has received research grants and/or consultancy 
honoraria from Abbott, AstraZeneca, Eli-Lilly, GlaxoSmith-
Kline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, 
Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, 
Takeda, Tikvah, and Wyeth. The other authors report no 
conflicts of interest in this work.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5). Washington DC: American Psychiatric 
Association; 2013.
2. Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ. 
Skin picking disorder. Am J Psychiatry. 2012;169(11):1143–1149.
3. Hayes SL, Storch EA, Berlanga L. Skin picking behaviors: an examina-
tion of the prevalence and severity in a community sample. J Anxiety 
Disord. 2009;23(3):314–319.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
23
2.
12
5.
10
8 
on
 2
9-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1871
excoriation disorder: current treatment options
 4. Keuthen NJ, Koran LM, Aboujaoude E, Large MD, Serpe RT. The 
prevalence of pathologic skin picking in US adults. Compr Psychiatry. 
2010;51(2):183–186.
 5. Odlaug BL, Grant JE. Phenomenology and epidemiology of patho-
logical skin picking. In: Grant JE, Potenza MN, editors. The Oxford 
Library of Psychology: Oxford Handbook of Impulse Control Disorders. 
New York, USA: Oxford University Press, 2011:186–195.
 6. Bohne A, Keuthen N, Wilhelm S. Pathologic hairpulling, skin picking, 
and nail biting. Ann Clin Psychiatry. 2005;17(4):227–232.
 7. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. 
Clinical features, proposed diagnostic criteria, epidemiology and 
approaches to treatment. CNS Drugs. 2001;15(5):351–359.
 8. Neziroglu F, Rabinowitz D, Breytman A, Jacofsky M. Skin picking 
phenomenology and severity comparison. Prim Care Companion J Clin 
Psychiatry. 2008;10(4):306–312.
 9. Snorrason I, Smari J, Olafsson RP. Emotion regulation in pathological 
skin picking: findings from a non-treatment seeking sample. J Behav 
Ther Exp Psychiatry. 2010;41(3):238–245.
 10. Lochner C, Grant JE, Odlaug BL, Stein DJ. DSM-5 field survey: skin 
picking disorder. Ann Clin Psychiatry. 2012;24(4):300–304.
 11. Flessner CA, Woods DW. Phenomenological characteristics, social 
problems, and the economic impact associated with chronic skin 
picking. Behav Modif. 2006;30(6):944–963.
 12. Stein DJ, Lochner C. Obsessive-compulsive and related disorders. 
In: Sadock BJ, Sadock VA, Ruiz P, editors. Comprehensive Textbook 
of Psychiatry. Philadelphia, PA: Wolters Kluwer; 2017.
 13. Odlaug BL, Grant JE. Clinical characteristics and medical complica-
tions of pathologic skin picking. Gen Hosp Psychiatry. 2008;30(1): 
61–66.
 14. Kondziolka D, Hudak R. Management of obsessive-compulsive disorder-
related skin picking with gamma knife radiosurgical anterior capsulo-
tomies: a case report. J Clin Psychiatry. 2008;69(8):1337–1340.
 15. O’Sullivan RL, Phillips KA, Keuthen NJ, Wilhelm S. Near-fatal skin 
picking from delusional body dysmorphic disorder responsive to flu-
voxamine. Psychosomatics. 1999;40(1):79–81.
 16. Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic 
skin picking: an open-label study. J Clin Psychiatry. 2007;68(9): 
1384–1391.
 17. Schumer MC, Bartley CA, Bloch MH. Systematic review of pharma-
cological and behavioral treatments for skin picking disorder. J Clin 
Psychopharmacol. 2016;36(2):147–152.
 18. Selles RR, McGuire JF, Small BJ, Storch EA. A systematic review and 
meta-analysis of psychiatric treatments for excoriation (skin-picking) 
disorder. Gen Hosp Psychiatry. 2016;41:29–37.
 19. Miltenberger RG, Fuqua RW, Woods DW. Applying behavior analysis 
to clinical problems: review and analysis of habit reversal. J Appl Behav 
Anal. 1998;31(3):447–469.
 20. Schuck K, Keijsers GP, Rinck M. The effects of brief cognitive- 
behaviour therapy for pathological skin picking: a randomized compari-
son to wait-list control. Behav Res Ther. 2011;49(1):11–17.
 21. Teng EJ, Woods DW, Twohig MP. Habit reversal as a treatment for 
chronic skin picking: a pilot investigation. Behav Modif. 2006;30(4): 
411–422.
 22. Flessner CA, Mouton-Odum S, Stocker AJ, Keuthen NJ. StopPicking.
com: internet-based treatment for self-injurious skin picking. Dermatol 
Online J. 2007;13(4):3.
 23. Moritz S, Fricke S, Treszl A, Wittekind CE. Do it yourself! Evalua-
tion of self-help habit reversal training versus decoupling in patho-
logical skin picking: a pilot study. J Obsessive Compuls Relat Disord. 
2012;1:41–47.
 24. Twohig MP, Hayes SC, Masuda A. A preliminary investigation of 
acceptance and commitment therapy as a treatment for chronic skin 
picking. Behav Res Ther. 2006;44(10):1513–1522.
 25. Flessner CA, Busch AM, Heideman PW, Woods DW. Acceptance-
enhanced behavior therapy (AEBT) for trichotillomania and chronic 
skin picking: exploring the effects of component sequencing. Behav 
Modif. 2008;32(5):579–594.
 26. Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. 
A double-blind trial of fluoxetine in pathologic skin picking. J Clin 
Psychiatry. 1997;58(8):341–347.
 27. Bloch MR, Elliott M, Thompson H, Koran LM. Fluoxetine in pathologic 
skin-picking: open-label and double-blind results. Psychosomatics. 
2001;42:314–319.
 28. Sharma H. Psychogenic excoriation responding to fluoxetine: a case 
report. J Indian Med Assoc. 2008;106:245–262.
 29. Arbabi M, Farnia V, Balighi K, et al. Efficacy of citalopram in treat-
ment of pathological skin picking: a randomized double blind placebo 
controlled trial. Acta Med Iran. 2008;46(5):367–372.
 30. Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, 
Dougherty DD. Open-label escitalopram treatment for pathological 
skin picking. Int Clin Psychopharmacol. 2007;22(5):268–274.
 31. Arnold LM, Mutasim DF, Dwight MM, Lamerson CL, Morris EM, 
McElroy SL. An open clinical trial of fluvoxamine treatment of psy-
chogenic excoriation. J Clin Psychopharmacol. 1999;19(1):15–18.
 32. Kalivas J, Kalivas L, Gilman D, Hayden CT. Sertraline in the treatment 
of neurotic excoriations and related disorders. Arch Dermatol. 1996; 
132(5):589–590.
 33. Grant JE, Odlaug BL, Chamberlain SR, Kim SW. A double-blind, 
placebo-controlled trial of lamotrigine for pathological skin picking: 
treatment efficacy and neurocognitive predictors of response. J Clin 
Psychopharmacol. 2010;30(4):396–403.
 34. Grados MA, Atkins EB, Kovacikova GI, McVicar E. A selective review 
of glutamate pharmacological therapy in obsessive-compulsive and 
related disorders. Psychol Res Behav Manag. 2015;8:115–131.
 35. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modu-
lator, in the treatment of trichotillomania: a double-blind, placebo-
controlled study. Arch Gen Psychiatry. 2009;66(7):756–763.
 36. Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming 
disorders. J Clin Psychopharmacol. 2007;27(2):227–229.
 37. Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, 
Kim SW. N-Acetylcysteine in the treatment of excoriation disorder: 
a randomized clinical trial. JAMA Psychiatry. 2016;73(5):490–496.
 38. Sasso DA, Kalanithi PS, Trueblood KV, et al. Beneficial effects of 
the glutamate-modulating agent riluzole on disordered eating and 
pathological skin-picking behaviors. J Clin Psychopharmacol. 2006; 
26(6):685–687.
 39. Dodman NH, Shuster L, White SD, Court MH, Parker D, Dixon R. Use 
of narcotic antagonists to modify stereotypic self-licking, self-chewing, 
and scratching behavior in dogs. J Am Vet Med Assoc. 1988;193(7): 
815–819.
 40. White SD. Naltrexone for treatment of acral lick dermatitis in dogs. 
J Am Vet Med Assoc. 1990;196(7):1073–1076.
 41. Piquet-Pessoa M, Fontenelle LF. Opioid antagonists in broadly defined 
behavioral addictions: a narrative review. Expert Opin Pharmacother. 
2016;17(6):835–844.
 42. Seedat S, Stein DJ, Harvey BH. Inositol in the treatment of trichotil-
lomania and compulsive skin picking. J Clin Psychiatry. 2001;62(1): 
60–61.
 43. Turner GA, Sutton S, Sharma A. Augmentation of venlafaxine with 
aripiprazole in a case of treatment-resistant excoriation disorder. Innov 
Clin Neurosci. 2014;11(1–2):29–31.
 44. Christensen RC. Olanzapine augmentation of fluoxetine in the treat-
ment of pathological skin picking. Can J Psychiatry. 2004;49(11): 
788–789.
 45. Spiegel DR, Finklea L. The recognition and treatment of pathological 
skin picking: a potential neurobiological underpinning of the efficacy of 
pharmacotherapy in impulse control disorders. Psychiatry (Edgmont). 
2009;6(2):38–42.
 46. Luca M, Vecchio C, Luca A, Calandra C. Haloperidol augmentation of 
fluvoxamine in skin picking disorder: a case report. J Med Case Rep. 
2012;6:219.
 47. Torales J, Barrios I, Villalba J. Alternative therapies for excoriation 
(skin picking) disorder: a brief update. Adv Mind Body Med. 2017; 
31(1):10–13.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
23
2.
12
5.
10
8 
on
 2
9-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, 
and is the official journal of The International Neuropsychiatric 
 Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Neuropsychiatric Disease and Treatment 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1872
Lochner et al
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
23
2.
12
5.
10
8 
on
 2
9-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
